Gene Editing News and Research

RSS

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Doris Duke Innovations award for sickle cell disease research

Sangamo BioSciences, Inc. announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation.

1 Oct 2009

Zinc finger nucleases utilized for modifying hESCs and hiPSCs

Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).

8 Sep 2009

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

24 Aug 2009

In lung cancer, silencing one crucial gene disrupts normal functioning of genome

While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism.

1 Jan 2009

Why only some former smokers develop lung cancer

Canadian researchers are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar lifestyle changes.

17 Nov 2008

DNA modification seen in colorectal tumors helps predict outcomes, John Wayne Cancer Institute researchers find

An international study led by researchers at the John Wayne Cancer Institute at Saint John's Health Center has found that modifications to DNA found on multiple chromosomes in tumors can help to predict outcomes in patients with early-stage rectal cancer.

21 May 2008

Potential method for repairing misspelling in DNA code that causes spinal muscular atrophy

Researchers at the University of Delaware have discovered a novel technique - that acts like a "spell-checker" for correcting a misspelling in the DNA code - to repair the defective gene that causes spinal muscular atrophy (SMA).

12 Feb 2008

Sir Martin Evans wins Nobel prize for stem cell research

Medical Research Council funded scientist Sir Martin Evans, has been awarded the Nobel Prize in Physiology or Medicine for 2007 alongside Mario R. Capecchi and Oliver Smithies for their discoveries of "principles for introducing specific gene modifications in mice by the use of embryonic stem cells".

9 Oct 2007

Sigma-Aldrich launches Imprint DNA Modification kit

Sigma-Aldrich has announced the launch of the Imprint DNA Modification kit.

11 Jul 2007

New biotech company develops UD-patented technologies for repairing genes

OrphageniX Inc., a new biotechnology company founded by University of Delaware researchers, has been established in Wilmington to develop and commercialize UD-patented technologies for repairing genes that cause rare, hereditary diseases such as sickle cell anemia and spinal muscular atrophy.

25 Apr 2007

Human proteins evolving slowly thanks to multi-tasking genes

Many human proteins are not as good as they might be because the gene sequences that code for them have a double role which slows down the rate at which they evolve, according to new research published in PLoS Biology.

6 Feb 2007

Federally approved human embryonic stems inferior to those donated for research

Neural stem cells grown from one of the federally approved human embryonic stem cell lines proved to be inferior to neural stem cells derived from fetal tissue donated for research, a UCLA study has found.

4 Aug 2006

Researchers narrow search for effective prostate cancer biomarkers

Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.

4 Apr 2006